Acid Sphingomyelinase Deficiency Market Summary

Acid Sphingomyelinase Deficiency (ASMD) Insights and Trends

• Acid Sphingomyelinase Deficiency (ASMD) exhibits a broad clinical spectrum ranging from rapidly progressive infantile neurovisceral disease (Type A) with early mortality to chronic visceral disease (Type B) compatible with survival into adulthood.
• ASMD remains significantly underdiagnosed due to phenotypic heterogeneity and overlap with other lysosomal storage disorders, despite an estimated prevalence of approximately 1 in 250,000 individuals globally. However, increasing genetic testing and physician awareness are improving identification of both pediatric and adult-onset cases across the 7MM.
• Until a few years ago, ASMD treatment was primarily limited to symptomatic management and bone marrow or solid organ transplantation (liver and/or lung). 
• In 2022, the approval of olipudase alfa (XENPOZYME) has transformed the ASMD treatment landscape by becoming the first disease-specific enzyme replacement therapy (ERT) for non-neuronopathic ASMD.
• Despite advances in systemic disease management, substantial unmet need persists for patients with neurological involvement, as currently available ERTs are unable to effectively penetrate the blood–brain barrier.
• The ASMD market is poised for growth with expanding global access to ERTs, increasing rare disease recognition, and ongoing research into next-generation therapies capable of addressing neurological involvement. 

Acid Sphingomyelinase Deficiency (ASMD) Market Size and Forecast in the 7MM

• 2025 ASMD Market Size: XX million
• 2036 Projected ASMD Market Size: XX million
• ASMD Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Acid Sphingomyelinase Deficiency (ASMD) – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the ASMD, historical and forecasted epidemiology, as well as the ASMD market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The ASMD market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates ASMD patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in ASMD and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Acid Sphingomyelinase Deficiency (ASMD) Market

• Approval and Commercialization of Disease-Specific Therapies

The approval of olipudase alfa by regulatory agencies such as the FDA and EMA has significantly transformed the ASMD treatment landscape. It is the first ERT specifically approved for non-central nervous system (CNS) manifestations of ASMD.

• Rising Awareness and Improved Diagnosis Rates

Increased awareness among healthcare professionals, patient advocacy groups, and rare disease organizations has improved early recognition and diagnosis of ASMD.

• Supportive Regulatory Environment for Orphan Diseases

Government incentives such as orphan drug designation, fast-track approvals, market exclusivity, and tax benefits in the US, Europe, and Japan are encouraging pharmaceutical companies to invest in ASMD therapeutics.

Acid Sphingomyelinase Deficiency (ASMD) Understanding and Treatment Algorithm

Acid Sphingomyelinase Deficiency (ASMD) Overview and Diagnosis

ASMD, historically known as Niemann-Pick disease types A, A/B, and B, is a rare inherited lysosomal storage disorder caused by mutations in the SMPD1 gene. These mutations result in deficiency of the acid sphingomyelinase enzyme, leading to accumulation of sphingomyelin within cells and progressive damage to multiple organs. ASMD presents as a clinical spectrum ranging from severe infantile neurovisceral disease (type A) to chronic visceral and chronic neurovisceral forms (types B and A/B). Common manifestations include hepatosplenomegaly, interstitial lung disease, thrombocytopenia, dyslipidemia, growth delay, and in severe forms, progressive neurological deterioration. The disease significantly impacts quality of life and survival, with symptom severity varying widely among patients.

Diagnosis of ASMD is often challenging because of its rarity and overlap with other metabolic or hematologic disorders. Patients typically undergo evaluation after presenting with unexplained enlarged liver and spleen, recurrent respiratory symptoms, or abnormal lipid profiles. Definitive diagnosis is established through measurement of acid sphingomyelinase (ASM) enzyme activity in leukocytes or fibroblasts, followed by confirmation using molecular genetic testing for SMPD1 mutations. Additional assessments such as pulmonary function tests, imaging studies, liver function evaluation, and biomarker analysis help determine disease severity and organ involvement. Increasing awareness, expanded genetic testing availability, and rare disease screening programs are improving early diagnosis and reducing diagnostic delays.

Further details are provided in the report.

Current Acid Sphingomyelinase Deficiency (ASMD) Treatment Landscape

Treatment of ASMD has evolved significantly with the development of disease-specific therapies. Historically, management was primarily supportive and focused on symptom control, including respiratory care, nutritional support, pain management, and monitoring of liver and pulmonary complications. The approval of olipudase alfa marked a major advancement, as it became the first ERT approved for non-CNS manifestations of ASMD. Clinical studies have demonstrated improvements in spleen and liver volume, pulmonary function, and overall disease burden with treatment. In addition, ongoing research into gene therapies, substrate reduction therapies, and novel biologics continues to expand the future therapeutic landscape for ASMD patients. 

Further details related to country-based variations are provided in the report.

Acid Sphingomyelinase Deficiency (ASMD) Unmet Needs

The section “unmet needs of ASMD” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Missed diagnosis due to the rarity of the disease
2. Limited treatment options
3. Poor prognosis
4. Lifelong disease burden, and others…..

Note: Comprehensive unmet needs insights in ASMD and their strategic implications are provided in the full report.

Acid Sphingomyelinase Deficiency (ASMD) Epidemiology

Key Findings from ASMD Epidemiological Analysis and Forecast

• In 2024, ASMD type B was the predominant subtype, accounting for ~63%, while non-type A cases represented ~29% and ASMD type A/B accounted for 8.2%.
• ASMD impacts both males and females equally, showing no significant gender disparity in its prevalence. 

Acid Sphingomyelinase Deficiency (ASMD) Drug Analysis & Competitive Landscape

The ASMD drug chapter provides a detailed, market-focused review of the approved therapies. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the ASMD treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the ASMD therapeutics market.

Approved Therapies for Acid Sphingomyelinase Deficiency (ASMD)

Olipudase alfa (XENPOZYME): Sanofi

XENPOZYME is the first therapy indicated specifically for the treatment of ASMD, and is currently the only approved treatment for this disease. The European Commission approved olipudase alfa as the first and only ERT for the treatment of ASMD in pediatric and adult patients with ASMD type A/B or ASMD type B. The approval was based on positive data from the ASCEND and ASCEND-Peds clinical trials, in which olipudase alfaE showed substantial and clinically relevant improvement in lung function and reduction of spleen and liver volumes, with a well-tolerated safety profile. The European Medicines Agency (EMA) granted olipudase alfa PRIority MEdicines (PRIME) designation. It has also received breakthrough and fast track designations in US, SAKIGAKE designation in Japan. Along with orphan drug designation in US, Europe, and Japan.

Note: Detailed marketed therapies assessment will be provided in the final report.

Acid Sphingomyelinase Deficiency (ASMD) Key Players and Market Leaders

• Sanofi

Acid Sphingomyelinase Deficiency (ASMD) Market Outlook

The treatment landscape for ASMD has historically been limited to supportive and symptomatic management, including respiratory support, lipid-lowering therapies, pain management, nutritional care, and monitoring of hepatic and pulmonary complications. A major breakthrough occurred with the approval of olipudase alfa, developed by Sanofi. It is a recombinant human acid sphingomyelinase ERT designed to address the underlying enzyme deficiency in ASMD. As the first disease-specific enzyme replacement therapy (ERT) for non-CNS manifestations of ASMD, olipudase alfa demonstrated significant improvements in organ volume reduction and pulmonary function, marking a major shift toward targeted treatment approaches in ASMD.

However, despite this advancement, the emerging pipeline of ASMD remains very scarce highlighting a substantial unmet need and significant opportunity for future innovation in ASMD therapeutics.

Overall, the launch of olipudase alfa, expanding patient identification efforts, and rising awareness among healthcare professionals are expected to support steady market growth across the 7MM from 2022 to 2036, yielding significant commercial opportunities for existing products and pipeline candidates.

• The ASMD market in 7MM remains highly underserved, with substantial unmet need persisting particularly in neuronopathic/CNS manifestations where current ERT shows limited benefit.
• The US is expected to remain the largest ASMD market within the 7MM, supported by higher diagnosed prevalence, stronger rare disease infrastructure, and favorable reimbursement pathways.
• Olipudase alfa remains the first and only approved disease-specific therapy for non-CNS manifestations of ASMD across 7MM, significantly transforming the treatment landscape.

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in ASMD (2022–2036 Forecast)

The ASMD market (2022–2036 forecast) is primarily driven by the development of targeted ERT aimed at addressing the underlying deficiency of acid sphingomyelinase rather than relying solely on supportive care.

• ERT: The ASMD treatment landscape currently centers around olipudase alfa, developed by Sanofi. It is a recombinant human acid sphingomyelinase designed to replace the deficient enzyme responsible for sphingomyelin accumulation in tissues. By restoring enzymatic activity, Olipudase alfa helps reduce sphingomyelin storage in organs such as the spleen, liver, and lungs, thereby improving organ function and disease outcomes. 

ASMD innovation is currently driven by ERT focused on correcting the underlying enzymatic defect, representing a significant shift toward disease-modifying treatment strategies in this rare lysosomal storage disorder.

Acid Sphingomyelinase Deficiency (ASMD) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the ASMD drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

During the forecast period, drug uptake in ASMD is expected to increase gradually, driven by improved disease awareness, biomarker-based screening, and broader access to disease-specific therapies. Olipudase alfa is expected to remain the cornerstone of the ASMD treatment landscape throughout the forecast period. As a recombinant human acid sphingomyelinase ERT, it directly addresses the underlying enzyme deficiency responsible for sphingomyelin accumulation. Its uptake is anticipated to expand steadily, particularly in patients with non-CNS manifestations of ASMD, supported by clinical evidence demonstrating improvements in pulmonary function, spleen and liver volume reduction, and overall disease burden.

Overall, ASMD market growth is expected to be driven primarily by increasing adoption of ERT, advancements in rare disease diagnostics, improved physician awareness, and expanding access to specialized treatment centers. However, uptake may remain moderate due to the rarity of the disease, high treatment costs, and the need for long-term monitoring and specialized care.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Acid Sphingomyelinase Deficiency (ASMD)

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The United States

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report….

Acid Sphingomyelinase Deficiency (ASMD) Therapies Price Scenario & Trends 

Pricing and analogue assessment of ASMD therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Acid Sphingomyelinase Deficiency (ASMD) 

To keep up with ASMD market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the ASMD emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in ASMD, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights at the country level. Centers such as Icahn School of Medicine at Mount Sinai, Genetic Disease Foundation, University Medical Center Hamburg-Eppendorf, etc. were contacted. Their opinion helps understand and validate current and emerging ASMD therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in ASMD.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. 

In the SWOT analysis of ASMD, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of ASMD, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the ASMD market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM ASMD market. 

Report Insights

• Acid Sphingomyelinase Deficiency (ASMD) Patient Population Forecast
• Acid Sphingomyelinase Deficiency (ASMD) Therapeutics Market Size 
• Acid Sphingomyelinase Deficiency (ASMD) Pipeline Analysis
• Acid Sphingomyelinase Deficiency (ASMD) Market Size and Trends
• Acid Sphingomyelinase Deficiency (ASMD) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 
• Acid Sphingomyelinase Deficiency (ASMD) Market Outlook (North America, Europe, Asia-Pacific) 
• Patient Burden Trends (By Geography)
• Acid Sphingomyelinase Deficiency (ASMD) Treatment Addressable Market (TAM)
• Acid Sphingomyelinase Deficiency (ASMD) Competitve Landscape
• Acid Sphingomyelinase Deficiency (ASMD)) Major Companies Insights
• Acid Sphingomyelinase Deficiency (ASMD) Price Trends and Analogue Assessment
• Acid Sphingomyelinase Deficiency (ASMD) Therapies Drug Adoption/Uptake
• Acid Sphingomyelinase Deficiency (ASMD) Therapies Peak Patient Share Analysis

Report Assessment

• Acid Sphingomyelinase Deficiency (ASMD) Current Treatment Practices
• Acid Sphingomyelinase Deficiency (ASMD) Unmet Needs
• Acid Sphingomyelinase Deficiency (ASMD) Clinical Development Analysis
• Acid Sphingomyelinase Deficiency (ASMD) Emerging Drugs Product Profiles
• Acid Sphingomyelinase Deficiency (ASMD) Market attractiveness
• Acid Sphingomyelinase Deficiency (ASMD) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

Market Insights

• What was the ASMD market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of ASMD?
• What are the disease risks, burdens, and unmet needs of ASMD? What will be the growth opportunities across the 7MM concerning the patient population with ASMD?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of ASMD? What are the current guidelines for treating ASMD in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the ASMD market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)-enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data-driven decisions.